Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard A. Easom is active.

Publication


Featured researches published by Richard A. Easom.


Journal of Clinical Investigation | 1991

Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels.

Bryan A. Wolf; John R. Williamson; Richard A. Easom; K Chang; William R. Sherman; John Turk

The present experiments were undertaken to examine the hypothesis that glucose-induced increased de novo synthesis of 1,2-diacyl-sn-glycerol (which has been observed in a number of different tissues, including retinal capillary endothelial cells exposed to elevated glucose levels in vitro) and associated activation of protein kinase C may play a role in mediating glucose-induced vascular functional changes. We report here that twice daily instillation of 30 mM glucose over 10 d in a rat skin chamber granulation tissue model induces approximately a 2.7-fold increase in diacylglycerol (DAG) levels (versus tissues exposed to 5 mM glucose) in association with marked increases in vascular clearance of albumin and blood flow. The glucose-induced increase in DAG levels as well as the vascular functional changes are prevented by addition of 3 mM pyruvate. Pharmacological activation of protein kinase C with the phorbol ester TPA in the presence of 5 mM glucose increases microvascular albumin clearance and blood flow, and similar effects are observed with 1-monoolein (MOG), a pharmacological inhibitor of the catabolism of endogenous DAG. A pharmacological inhibitor of protein kinase C (staurosporine) greatly attenuates the rise in microvascular albumin clearance (but not the rise in blood flow) induced by glucose or by MOG. These findings are compatible with the hypothesis that elevated concentrations of glucose increase tissue DAG content via de novo synthesis, resulting in protein kinase C activation, and that these biochemical events are among the factors that generate the increased microvascular albumin clearance.


Journal of Clinical Investigation | 1990

Interleukin 1 inhibits insulin secretion from isolated rat pancreatic islets by a process that requires gene transcription and mRNA translation.

Jonathan H. Hughes; Jerry R. Colca; Richard A. Easom; John Turk; Michael L. McDaniel

Recombinant human IL 1 beta inhibits glucose-induced insulin secretion from isolated pancreatic islets and from purified beta-cells obtained by fluorescence-activated cell sorting (FACS) of dispersed islet cells. Brief (1 h) exposure of isolated islets to IL 1 produces sustained inhibition of insulin secretion for at least 17 h after the IL 1 has been removed from the culture medium. An inhibitory effect of IL 1 on insulin secretion is not observed when islets are coincubated with an inhibitor of DNA transcription (actinomycin D). This finding indicates that the inhibitory effect of IL 1 on insulin secretion requires transcription of one or more genes during the first hour of exposure of islets to IL 1. The inhibitory effect of IL 1 on insulin secretion also requires mRNA translation, because three structurally distinct inhibitors of protein synthesis (cycloheximide, anisomycin, and puromycin) prevent IL 1-induced inhibition of insulin secretion when added to islets after the 1-h exposure to IL 1. Two-dimensional gel electrophoresis of islet proteins metabolically labeled with [35S]methionine demonstrates that IL 1 augments the expression of a 65-kD (pl approximately 6.5) protein by greater than 2.5-fold. These findings indicate that biochemical events occurring within 1 h of exposure of islets to IL 1 lead to an inhibition of insulin secretion that persists for at least 17 h after the removal of IL 1. One of the early biochemical effects of IL 1 on islets is gene transcription (0-1 h), which is followed by mRNA translation (after 1 h). Our results suggest that the inhibitory effect of IL 1 on insulin secretion is mediated by protein(s) whose synthesis is induced by IL 1.


Journal of Biological Chemistry | 1997

Calcium-stimulated Phosphorylation of MAP-2 in Pancreatic βTC3-cells Is Mediated by Ca2+/Calmodulin-dependent Kinase II

Kimberly A. Krueger; Harshika S. Bhatt; Michael Landt; Richard A. Easom

An understanding of the role of CaM kinase II in the pancreatic β-cell is dependent on the identification of its cellular targets. One of the best substrates of CaM kinase II in vitro that could function in secretory events is the microtubule-associated protein, MAP-2. By immunoblot analysis, a high molecular weight protein with electrophoretic properties characteristic of MAP-2, was identified in rat insulinoma βTC3 cells and isolated rat islets. In immunoprecipitation experiments employing α-toxin-permeabilized βTC3 cells, elevation of intracellular Ca2+ or addition of forskolin, an adenylate cyclase activator, induced significant phosphorylation of MAP-2 in situ. The effect of Ca2+ was rapid, concentration-dependent and closely correlated with activation of CaM kinase II under similar experimental conditions. H-89, a specific and potent inhibitor of cAMP-dependent protein kinase (PKA), prevented forskolin-induced MAP-2 phosphorylation but had little effect on MAP-2 phosphorylation stimulated by elevated Ca2+. Phosphopeptide mapping revealed that the phosphorylation pattern observed in situ upon incubation of the βTC3 cells with increased free Ca2+, was strikingly similar to that generated in vitro by CaM kinase II, most notably with regard to the increased phosphate incorporated into one prominent site. These data provide evidence that MAP-2 is phosphorylated by CaM kinase II in the pancreatic β-cell in situ, and that this event may provide an important link in the mediation of Ca2+-dependent insulin secretion.


Journal of Clinical Investigation | 1990

Diacylglycerol synthesis de novo from glucose by pancreatic islets isolated from rats and humans.

Bryan A. Wolf; Richard A. Easom; Michael L. McDaniel; John Turk

Recent evidence has suggested that pancreatic islets isolated from rats synthesize 1,2-diacyl-sn-glycerol (DAG) de novo from glucose and that this process may constitute the long-sought link between the metabolism of glucose and the induction of insulin secretion. The cell-permeant diacylglycerol 1-oleoyl-2-acetyl-sn-glycerol (200 microM) has been found here to amplify both the first and second phases of insulin secretion from perifused human islets. Measurements of the mass of endogenous DAG in human pancreatic islets by enzymatic and by mass spectrometric methods indicate that levels of 200 microM may be achieved under physiologic conditions. Conversion of [14C]glucose to [14C]DAG has been demonstrated here to occur within 60 s of exposure of rat and human islets to stimulatory concentrations of glucose. This process has been found to be a quantitatively minor contributor to the total islet DAG mass after acute stimulation with glucose, however, and glucose has been found not to induce a rise in total islet DAG content within 20 min of induction of insulin secretion. In contrast to the case with rodent islets, two pharmacologic inhibitors of DAG-induced activation of protein kinase C (staurosporine and sphingosine) have been found not to influence glucose-induced insulin secretion from isolated human islets. These findings indicate that de novo synthesis of DAG from glucose does not participate in acute signal-response coupling in islets.


Diabetes | 1988

Descriptive and Mechanistic Considerations of Interleukin 1 and Insulin Secretion

Michael L. McDaniel; Jonathan H. Hughes; Bryan A. Wolf; Richard A. Easom; John Turk

Insulin-dependent diabetes mellitus (IDDM) may be mediated in part by an autoimmune mechanism, as suggested by associated cytologie and serologie phenomena, e.g., insulitis, β-cell necrosis, and the presence of both islet cell and insulin antibodies. Immunological approaches to the prediction and intervention in the progression of β-cell destruction in this disease are under evaluation. A recent hypothesis is that cytokines, including interleukin 1 (IL-1), play causative roles in such autoimmune processes. Several studies have convincingly demonstrated that IL-1 is a potent modulator of β-cell function and can potentiate or inhibit glucose-induced insulin secretion, depending on the concentration and length of exposure to IL-1. IL-1 alone or in concert with other cytokines is cytotoxic to β-cells. The cellular mechanisms responsible for the potent effects of IL-1 on the β-cell are unknown and just beginning to emerge. Although speculative at this time, this perspective delineates cellular mechanisms that are likely to represent possible primary sites for the IL-1 action on β-cells. A mechanistic understanding of the effects of IL-1 on the β-cell may clarify its role in modulating insulin release in vivo or yield insight into the pathogenesis of IDDM.


Diabetes | 1989

Interleukin 1-induced prostaglandin E2 accumulation by isolated pancreatic islets

Jonathan H. Hughes; Richard A. Easom; Bryan A. Wolf; John Turk; Michael L. McDaniel

Recombinant human interleukin 1α (IL-1) has been found to induce prostaglandin E2 (PGE2) accumulation by isolated rat islets of Langerhans at concentrations similar to those at which the cytokine inhibits glucoseinduced insulin secretion and islet glucose oxidation. Maximal stimulation of PGE2 accumulation (5 times control value) occurred at 200 pM IL-1, and halfmaximal stimulation occurred at 25 pM IL-1. Significant augmentation of PGE2 accumulation by IL-1 required 10–18 h of exposure to the cytokine. Islets that had been pretreated with IL-1 for 18 h showed elevated rates of PGE2 production at basal (3-mM) and stimulatory (16.5-mM) glucose concentrations and converted exogenous arachidonic acid to PGE2 at twice the maximal rate of control islets. Exogenous PGE2 did not mimic the inhibitory effects of IL-1 on glucose-induced insulin secretion or glucose oxidation. To rule out the possibility that endogenous PGE2 is involved in the inhibitory effects of IL-1, the effect of a cyclooxygenase inhibitor on IL-1-treated islets was examined. Pharmacological blockade of PGE2 biosynthesis by 10 JAM indomethacin did not influence the inhibitory effects of IL-1 on glucoseinduced insulin secretion or glucose oxidation. Thus, exogenous PGE2 does not mimic the effects of IL-1 on islets, and inhibition of endogenous PGE2 biosynthesis does not suppress the effects of IL-1 on islets. These results suggest that PGE2 is not a principal mediator of the inhibitory effects of IL-1 on glucose-induced insulin secretion or glucose oxidation.


Diabetes | 1988

Arachidonic Acid Metabolism and Insulin Secretion by Isolated Human Pancreatic Islets

John Turk; Jonathan H. Hughes; Richard A. Easom; Bryan A. Wolf; David W. Scharp; Paul E. Lacy; Michael L. McDaniel

Isolated human pancreatic islets converted [3H8]arachidonate to compounds with the high-performance liquid-chromatographic mobility of cyclooxygenase products, including prostaglandin E2(PGE2), PGF2α, and the lipoxygenase product 12-HETE. Human islet synthesis of PGE2, PGF2α, and 12-HETE from endogenous arachidonate was demonstrated with stable isotope dilution-gas chromatographic-negative ion-chemical ionization-mass spectrometric analysis. Pharmacologie inhibition of arachidonate metabolism by both lipoxygenase and cyclooxygenase pathways with BW 755C strongly suppressed glucose-induced insulin secretion from perifused human islets, and the selective cyclooxygenase inhibitor indomethacin enhanced insulin secretion. These findings are similar to those reported for islets isolated from rats and suggest that arachidonate metabolites may modulate glucose-induced insulin secretion in humans.


Cell Calcium | 1992

Parallel effects of arachidonic acid on insulin secretion, calmodulin-dependent protein kinase activity and protein kinase C activity in pancreatic islets

Michael Landt; Richard A. Easom; Jerry R. Colca; Bryan A. Wolf; John Turk; L.A Mills; Michael L. McDaniel

A potential role of arachidonic acid in the modulation of insulin secretion was investigated by measuring its effects on calmodulin-dependent protein kinase and protein kinase C in islet subcellular fractions. The results were interpreted in the light of arachidonic acid effects on insulin secretion from intact islets. Arachidonic acid could replace phosphatidylserine in activation of cytosolic protein kinase C (K0.5 of 10 microM) and maximum activation was observed at 50 microM arachidonate. Arachidonic acid did not affect the Ca2+ requirement of the phosphatidylserine-stimulated activity. Arachidonic acid (200 microM) inhibited (greater than 90%) calmodulin-dependent protein kinase activity (K0.5 = 50-100 microM) but modestly increased basal phosphorylation activity (no added calcium or calmodulin). Arachidonic acid inhibited glucose-sensitive insulin secretion from islets (K0.5 = 24 microM) measured in static secretion assays. Maximum inhibition (approximately 70%) was achieved at 50-100 microM arachidonic acid. Basal insulin secretion (3 mM glucose) was modestly stimulated by 100 microM arachidonic acid but in a non-saturable manner. In perifusion secretion studies, arachidonic acid (20 microM) had no effect on the first phase of glucose-induced secretion but nearly completely suppressed second phase secretion. At basal glucose (4 mM), arachidonic acid induced a modest but reproducible biphasic insulin secretion response which mimicked glucose-sensitive secretion. However, phosphorylation of an 80 kD protein substrate of protein kinase C was not increased when intact islets were incubated with arachidonic acid, suggesting that the small increases in insulin secretion seen with arachidonic acid were not mediated by protein kinase C. These data suggest that arachidonic acid generated by exposure of islets to glucose may influence insulin secretion by inhibiting the activity of calmodulin-dependent protein kinase but probably has little effect on protein kinase C activity.


FEBS Letters | 1990

Interleukin-1 induces rapid and transient expression of the c-fos proto-oncogene in isolated pancreatic islets and in purified β-cells

Jonathan H. Hughes; Mark A. Watson; Richard A. Easom; John Turk; Michael L. McDaniel

The effect of interleukin‐1β (IL‐1) on expression of c‐fos mRNA in isolated rat pancreatic islets was examined. Accumulation of c‐fos mRNA was demonstrable after 30 min of exposure to IL‐1, peaked by 60 min, and declined thereafter. Fluorescence‐activated cell sorting (FACS) of dispersed islet cells was employed to localize the accumulation of c‐fos mRNA to the β‐cell. Cycloheximide did not influence the induction of c‐fos mRNA by IL‐1. Accumulation of c‐fos mRNA therefore appears to be an early signal transduction event in the β‐cell and a component of the cellular mechanism(s) by which IL‐1 influences β‐cell function.


Biochemical and Biophysical Research Communications | 1990

Evidence for a role of microfilaments in insulin release from purified β-cells

Jin-Lin Wang; Richard A. Easom; Jonathan H. Hughes; Michael L. McDaniel

Abstract To determine if the failure of purified β-cells to secrete insulin in response to a glucose stimulus results from the absence of a cytoskeletal response, the effects of cytochalasins D and B on glucose-induced insulin release were investigated. Glucose alone failed to stimulate insulin release whereas glucose in the presence of glucagon, theophylline, cytochalasin D or B markedly potentiated insulin release. Cytochalasin D potentiated insulin secretion in a dose-dependent manner, and the combination of theophylline and cytochalasin D resulted in an insulin secretory response no greater than that produced by either agent alone. Both glucagon and theophylline are believed to mediate their effectsvia cAMP, however, cytochalasin D did not affect β-cell cAMP levels. These results suggest that the inability of purified β-cells to release insulin may result from the absence of the necessary modulation of the state of the microfilaments.

Collaboration


Dive into the Richard A. Easom's collaboration.

Top Co-Authors

Avatar

John Turk

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Michael L. McDaniel

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Jonathan H. Hughes

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Bryan A. Wolf

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Michael Landt

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Harshika S. Bhatt

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

David W. Scharp

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Jin-Lin Wang

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge